{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:44:56Z","timestamp":1793295896907,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Transplant."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication of solid organ transplantation associated with long-term immunosuppression and Epstein\u2013Barr virus (EBV) reactivation. This study analyses the clinical presentation, diagnostic pathways, therapeutic strategies and outcomes of PTLD in renal and pancreatic transplant recipients at the Manchester Centre for Transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was carried out on a cohort of 73 patients diagnosed with PTLD between 2002 and 2025 following renal, simultaneous pancreas-kidney (SPK) or pancreas-only transplantation. Data were collected from electronic medical records and analysed descriptively. Clinical presentations were categorised into organ system involvement. Time from presentation to diagnosis and survival outcomes were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median time from transplant to PTLD diagnosis was 132 months, with 56% of cases diagnosed more than 10 years post-transplant. Monomorphic PTLD, in particular diffuse large B-cell lymphoma (DLBCL), was the most common subtype. EBV-positivity was seen in all early cases and in 57% overall. Abdominal and B symptoms were the most frequent presentations. Bleeding and\/or anaemia were significantly associated with diagnostic delay (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.045), and delays over one month were associated with reduced survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.061). Complete or partial remission was achieved in 75% of patients. The 5-year overall survival rate was 68% while 1-year survival was 83% and death-censored graft survival was 82%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In our cohort, PTLD in transplant recipients presents with diverse symptoms and can occur several years post-transplant highlighting the need for long-term vigilance. Streamlined referral pathways and increased awareness could reduce diagnostic delays. Establishing a national PTLD registry would benefit future research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/frtra.2026.1830197","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:52:18Z","timestamp":1781675538000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical presentation, management, and outcomes of post-transplant lymphoproliferative disorder in renal and pancreas transplantation: a 22-year experience"],"prefix":"10.3389","volume":"5","author":[{"given":"Kian","family":"Emami","sequence":"first","affiliation":[{"name":"Faculty of Biology, Medicine and Health, The University of Manchester","place":["Manchester, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Norman","sequence":"additional","affiliation":[{"name":"Department of Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust","place":["Manchester, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titus","family":"Augustine","sequence":"additional","affiliation":[{"name":"Manchester Centre for Transplantation, Manchester Royal Infirmary, Manchester University NHS Foundation Trust","place":["Manchester, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1634\/theoncologist.11-6-674","article-title":"Post-transplant lymphoproliferative disorders","volume":"11","author":"LaCasce","year":"2006","journal-title":"Oncologist"},{"key":"B2","doi-asserted-by":"publisher","first-page":"15088","DOI":"10.1038\/nrdp.2015.88","article-title":"Post-transplant lymphoproliferative disorders","volume":"2","author":"Dharnidharka","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/j.1600-6143.2011.03499.x","article-title":"Epstein\u2013barr virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy","volume":"11","author":"Nourse","year":"2011","journal-title":"Am J Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"B5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/01.TP.0000165098.49658.F3","article-title":"Lymphoproliferative disease after renal transplantation in Australia and New Zealand","volume":"80","author":"Faull","year":"2005","journal-title":"Transplantation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.3109\/10428194.2013.780655","article-title":"Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors","volume":"54","author":"Dierickx","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/ajt.14603","article-title":"Comprehensive review of post-organ transplant hematologic cancers","volume":"18","author":"Dharnidharka","year":"2018","journal-title":"Am J Transplant"},{"key":"B8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.4103\/1319-2442.206456","article-title":"Postrenal transplant malignancy: incidence, risk factors, and prognosis","volume":"28","author":"Elserwy","year":"2017","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/j.transproceed.2018.02.168","article-title":"Posttransplant lymphoproliferative disorder in kidney and liver transplant recipients: a single-center experience","volume":"50","author":"W\u00f3jciak","year":"2018","journal-title":"Transplant Proc"},{"key":"B10","doi-asserted-by":"publisher","first-page":"810.e7","DOI":"10.1016\/j.jvoice.2020.01.014","article-title":"Post-transplant lymphoproliferative disease (PTLD) of the larynx in an adult with kidney transplant: a case report","volume":"35","author":"El-Natout","year":"2021","journal-title":"J Voice"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1208028","DOI":"10.3389\/fonc.2023.1208028","article-title":"Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study","volume":"13","author":"L\u00fcckemeier","year":"2023","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/00007890-198505000-00001","article-title":"Epstein\u2013barr virus, immunodeficiency, and B cell lymphoproliferation","volume":"39","author":"Hanto","year":"1985","journal-title":"Transplantation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/TP.0b013e3181b9692d","article-title":"Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma","volume":"88","author":"Opelz","year":"2009","journal-title":"Transplantation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1093\/ndt\/gfr769","article-title":"Impact of epstein\u2013barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients","volume":"27","author":"Sampaio","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/clinids\/20.5.1346","article-title":"Pretransplantation assessment of the risk of lymphoproliferative disorder","volume":"20","author":"Walker","year":"1995","journal-title":"Clin Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1097\/TP.0000000000002146","article-title":"The changing epidemiology of posttransplant lymphoproliferative disorder in adult solid organ transplant recipients over 30 years: a single-center experience","volume":"102","author":"Peters","year":"2018","journal-title":"Transplantation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1182\/blood-2009-02-202507","article-title":"Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation","volume":"114","author":"van Leeuwen","year":"2009","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1111\/ajt.13324","article-title":"The impact of EBV Status on characteristics and outcomes of posttransplantation lymphoproliferative disorder","volume":"15","author":"Luskin","year":"2015","journal-title":"Am J Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/j.1600-6143.2006.01294.x","article-title":"Post-Transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival","volume":"6","author":"Kremers","year":"2006","journal-title":"Am J Transplant"},{"key":"B20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.5500\/wjt.v12.i8.268","article-title":"Gastrointestinal manifestations, risk factors, and management in patients with post-transplant lymphoproliferative disorder: a systematic review","volume":"12","author":"Reiche","year":"2022","journal-title":"World J Transplant"},{"key":"B21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/00000658-196908000-00011","article-title":"Primary lymphoma of the gastrointestinal tract: a review of 100 cases","volume":"170","author":"Loehr","year":"1969","journal-title":"Ann Surg"},{"key":"B22","volume-title":"Post-transplant Lymphoproliferative Disorders (PTLD): WHO 2017 Classification Schema","year":""},{"key":"B23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-Transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/bjh.17421","article-title":"Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients\u2014a British society for haematology guideline","volume":"193","author":"Shah","year":"2021","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-2141.2010.08160.x","article-title":"Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients\u2014bCSH and BTS guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(84)90994-2","article-title":"Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy","volume":"323","author":"Starzl","year":"1984","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1111\/j.1600-6143.2009.02772.x","article-title":"Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression","volume":"9","author":"Trappe","year":"2009","journal-title":"Am J Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1182\/blood.2023020075","article-title":"How I treat posttransplant lymphoproliferative disorder","volume":"142","author":"Amengual","year":"2023","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/infdis\/152.5.876","article-title":"Epstein\u2013barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection","volume":"152","author":"Ho","year":"1985","journal-title":"J Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11912-010-0132-1","article-title":"Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy","volume":"12","author":"Evens","year":"2010","journal-title":"Curr Oncol Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1600-6143.2011.03896.x","article-title":"Epidemiology of post transplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas","volume":"12","author":"Caillard","year":"2012","journal-title":"Am J Transplant"},{"key":"B32","doi-asserted-by":"publisher","first-page":"96903","DOI":"10.18632\/oncotarget.18890","article-title":"Posttransplant lymphoproliferative disorders in kidney transplant recipients: a retrospective cohort analysis over two decades in Hong Kong","volume":"8","author":"Cheung","year":"2017","journal-title":"Oncotarget"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.transproceed.2022.10.017","article-title":"Incidence of lymphoproliferative disorders after renal transplantation is down, but the poor prognosis remains: a multicenter 32-year cohort study","volume":"54","author":"Franco","year":"2022","journal-title":"Transplant Proc"},{"key":"B34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5144\/1658-3876.2011.10","article-title":"Early versus late onset of lymphoproliferative disorders post-heart and lung transplantation: the PTLD","volume":"4","author":"Khedmat","year":"2011","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1182\/blood-2022-160147","article-title":"Prevalence and characterization of EBV-negative post-transplant lymphoproliferative disorder","volume":"140","author":"Ford","year":"2022","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.5603\/ahp.101636","article-title":"Tabelecleucel: a new therapeutic option in refractory EBV-PTLD","volume":"55","author":"Styczy\u0144ski","year":"2024","journal-title":"Acta Haematol Pol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/bjh.18828","article-title":"Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed\/refractory solid organ transplant-related PTLD","volume":"202","author":"McKenna","year":"2023","journal-title":"Br J Haematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.clml.2023.05.007","article-title":"CAR T cell therapy for post-transplant lymphoproliferative disorder after solid organ transplantation: a safe and feasible therapy for an orphan disease","volume":"23","author":"Ibrahim","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B40","doi-asserted-by":"publisher","first-page":"73.e1","DOI":"10.1016\/j.jtct.2023.05.018","article-title":"Efficacy and toxicity of CD19 chimeric antigen receptor T cell therapy for lymphoma in solid organ transplant recipients: a systematic review and meta-analysis","volume":"30","author":"Yamshon","year":"2024","journal-title":"Transplant Cell Ther"}],"container-title":["Frontiers in Transplantation"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2026.1830197\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:52:18Z","timestamp":1781675538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2026.1830197\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":40,"alternative-id":["10.3389\/frtra.2026.1830197"],"URL":"https:\/\/doi.org\/10.3389\/frtra.2026.1830197","relation":{},"ISSN":["2813-2440"],"issn-type":[{"value":"2813-2440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1830197"}}